Across TCGA pan-cancer cohorts, SESTD1 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of SESTD1’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where SESTD1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SESTD1 is over-expressed in tumor, although a few such as LUSC and LUAD show the opposite, repressed pattern.
LIHC, LUSC, and KIRP are the cancer types where SESTD1 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SESTD1 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.